BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 15571958)

  • 21. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
    Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
    Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
    Cunsolo CL; Bicocchi MP; Petti AR; Tonini GP
    Br J Cancer; 2000 Nov; 83(10):1295-300. PubMed ID: 11044353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.
    Minard V; Hartmann O; Peyroulet MC; Michon J; Coze C; Defachelle AS; Lejars O; Perel Y; Bergeron C; Boutard P; Leverger G; Stephan JL; Thyss A; Chastagner P; Couillault G; Devalck C; Lutz P; Mechinaud F; Millot F; Plantaz D; Rialland X; Rubie H
    Br J Cancer; 2000 Oct; 83(8):973-9. PubMed ID: 10993641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
    Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
    Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction.
    Crabbe DC; Peters J; Seeger RC
    Diagn Mol Pathol; 1992 Dec; 1(4):229-34. PubMed ID: 1342970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid detection of MYCN gene amplification and telomerase expression in neuroblastoma.
    Hiyama E; Hiyama K; Yokoyama T; Fukuba I; Yamaoka H; Shay JW; Matsuura Y
    Clin Cancer Res; 1999 Mar; 5(3):601-9. PubMed ID: 10100712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
    McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
    Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall genomic pattern is a predictor of outcome in neuroblastoma.
    Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
    J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
    Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
    Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.
    George RE; Kenyon RM; McGuckin AG; Malcolm AJ; Pearson AD; Lunec J
    Oncogene; 1996 Apr; 12(7):1583-7. PubMed ID: 8622876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
    Gehring M; Berthold F; Edler L; Schwab M; Amler LC
    Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYCN amplification does not affect survival of neuroblastoma patients treated with autologous bone marrow transplantation.
    Sansone R; Di Martino D; Lanino E; Dini G; Massimo L; Tonini GP
    Bone Marrow Transplant; 1991; 7 Suppl 3():133-5. PubMed ID: 1855077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation.
    Gross N; Beretta C; Peruisseau G; Jackson D; Simmons D; Beck D
    Cancer Res; 1994 Aug; 54(15):4238-42. PubMed ID: 7518353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma).
    Lorenzana AN; Zielenska M; Thorner P; Gerrie B; Weitzman S; Squire J
    Pediatr Pathol Lab Med; 1997; 17(6):875-83. PubMed ID: 9353827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
    Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
    Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.
    Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B
    J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.